How Low Can Gilenia Go? Panel Wants Reduced-Dose Phase IV Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee votes that the agency should approve the first-ever oral MS drug, but should require Novartis to study what it hopes will be a safer version of the product.